Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS

Table 7

	SAVOR TIMI 53	EXAMINE	TECOS
Primary composite CV end-points	HR 1.00 [CI: 0.89–1.12] [16]	HR 0.96 [CI: Upper Limit 1.16] [20]	HR 0.98 [CI: 0.88–1.09] [17]
Heart failure	HR 1.27 [CI: 1.07–1.51] [16]; FDA reanalysis: HR 1.16 [CI: 1.03–1.30] [22]	HR 1.07 [CI: 0.79–1.46] [20]; FDA reanalysis: HR 0.98 [CI: 0.84–1.13] [23]	HR 1.00 [CI: 0.83–1.20] [17]; Composite analysis: HR 1.02 [CI: 0.90–1.15] [17]
All-cause mortality (7-day death); MACE: risk	HR 1.23 [CI: 1.02–1.48] [22]	Higher risk of MACE in the following: (i) Smokers, DM duration >10 yrs., metformin nonusers, insulin users, moderate-to-severe renal insufficiency [23].; (ii) Patients from US and Canada [23].	HR 1.01 [CI: 0.90–1.14] [17]
Hypoglycemia	HR 1.16 [CI: 1.08–1.25] [16]	6.7% (A) versus 6.5% (P) [19]	HR 1.12 [CI: 0.89–1.40] SH [17]